Replies to post #90380 on Biotech Values

[dewophile]

idix

i think NVS (as well as others) wanted to see the 14 day data prior to making a decision
there just wasn't enough to go on imo with the 3 day "POC"
i also think the partner that can generate the most value out of the compound is one that can hit the ground running with a complementary direct acting antiviral much like roche has going with the INFORM trials